Predicta Biosciences
Predicta Biosciences provides blood-based, multiomic diagnostics that enable personalized treatment guidance and high-resolution monitoring for hematologic cancers. The company combines liquid biopsies and whole-genome sequencing of circulating tumor cells with multiomic immune profiling and an AI/ML engine that mines a growing patient database. It packages these capabilities as a precision oncology diagnostics and therapeutic-discovery platform serving healthcare providers and biopharma partners. The platform supports noninvasive disease monitoring, treatment decision support for immunotherapies, and in-house identification of novel immunotherapy targets.
Predicta Biosciences
Predicta Biosciences provides blood-based, multiomic diagnostics that enable personalized treatment guidance and high-resolution monitoring for hematologic cancers. The company combines liquid biopsies and whole-genome sequencing of circulating tumor cells with multiomic immune profiling and an AI/ML engine that mines a growing patient database. It packages these capabilities as a precision oncology diagnostics and therapeutic-discovery platform serving healthcare providers and biopharma partners. The platform supports noninvasive disease monitoring, treatment decision support for immunotherapies, and in-house identification of novel immunotherapy targets.
TL;DR
Location & focus: Boston-based diagnostics company focused on WGS-based cellular liquid biopsy for multiple myeloma and plasma cell dyscrasias
Flagship product: GenoPredicta — whole-genome sequencing-based clinical assay for blood and bone marrow
Use cases: Noninvasive disease monitoring, treatment decision support for immunotherapies, and discovery of immunotherapy targets
Founding year: 2023
Recent funding: Series A (Oct 2025); reported round about $23.4M; total funding reported ~$28.6M
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Diagnostics and monitoring for hematologic cancers (multiple myeloma and plasma cell dyscrasias); precision oncology and immunotherapy target discovery.
Founded
2023
Industry
Biotechnology Research
Tech Stack
Funding Track Record
23,400,000
Dealroom reports Series A amount $23.4M; Crunchbase lists Engine Ventures as lead
Investor Signal
“Backed by life-sciences and strategic investors including Engine Ventures, Illumina Ventures, Mass General Brigham Ventures, Binney Street Capital and others”